ALK and neuroblastoma: Further, combined treatment using DFMO with celecoxib (a nonsteroidal anti‐inflammatory drug) have synergistic antitumor effects in NB models exhibiting ALK mutation, MYCN amplification, and TP53 mutation with multidrug resistance.158